Search Results - "Mariko Ogura"

Mechanism of jet injector-induced plasmid DNA uptake: Contribution of shear stress and endocytosis by Miyazaki, Hiroshi, Ogura, Mariko, Sakaguchi, Yuko, Hasegawa, Takashi, Atobe, Shingo, Terai, Kazuhiro

“…[Display omitted] The administration of plasmid DNA (pDNA) using a pyro-drive jet injector allows gene expression in cells of the treated tissue; however, the…”
Get full text

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer by Wakatsuki, Takeru, Yamamoto, Noriko, Sano, Takeshi, Chin, Keisho, Kawachi, Hiroshi, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Matsushima, Tomohiro, Suenaga, Mitsukuni, Shinozaki, Eiji, Hiki, Naoki, Ishikawa, Yuichi, Yamaguchi, Kensei

“…Background There is growing interest in the clinical significance of intratumoral HER2 heterogeneity. Its prognostic and predictive impacts on trastuzumab…”
Get full text

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study by Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru

“…Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53…”
Get full text

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival by Ota, Yumiko, Takahari, Daisuke, Suzuki, Takeshi, Osumi, Hiroki, Nakayama, Izuma, Oki, Akira, Wakatsuki, Takeru, Ichimura, Takashi, Ogura, Mariko, Shinozaki, Eiji, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Purpose In the ATTRACTION-2 trial, nivolumab significantly improved the survival of advanced gastric cancer patients. The pretreatment neutrophil-to-lymphocyte…”
Get full text

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research by Takahari, Daisuke, Shinozaki, Eiji, Wakatsuki, Takeru, Ooki, Akira, Ozaka, Masato, Suzuki, Takeshi, Nakayama, Izuma, Osumi, Hiroki, Kamiimabeppu, Daisaku, Sato, Taro, Ogura, Mariko, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of…”
Get full text

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer by Yagi, Shusuke, Wakatsuki, Takeru, Yamamoto, Noriko, Chin, Keisho, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Fujisaki, Junko, Ishikawa, Yuichi, Yamaguchi, Kensei, Namikawa, Ken, Horiuchi, Yusuke

“…Background We recently reported the clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using surgical specimens; patients with…”
Get full text

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer by Matsusaka, Satoshi, Chìn, Keisho, Ogura, Mariko, Suenaga, Mitsukuni, Shinozaki, Eiji, Mishima, Yuji, Terui, Yasuhito, Mizunuma, Nobuyuki, Hatake, Kiyohiko

“…The purpose of this study was to quantify circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients, and to demonstrate the role of CTCs in…”
Get full text

Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma by Suzuki, Takeshi, Okamura, Akihiko, Watanabe, Masayuki, Mine, Shinji, Imamura, Yu, Asari, Takao, Osumi, Hiroki, Nakayama, Izuma, Ichimura, Takashi, Ogura, Mariko, Ooki, Akira, Takahari, Daisuke, Yamaguchi, Kensei, Chin, Keisho

“…Background The optimal treatment strategy for patients with borderline resectable (BR) esophageal squamous cell carcinoma (ESCC), in which tumors grow very…”
Get full text

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer by Shimozaki, Keitaro, Shinozaki, Eiji, Yamamoto, Noriko, Imamura, Yu, Osumi, Hiroki, Nakayama, Izuma, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Ogura, Mariko, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

“…Purpose Although RAS and PIK3CA mutations have been associated with resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer,…”
Get full text

Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Takahari, Daisuke, Ooki, Akira, Suzuki, Takeshi, Ota, Yumiko, Nakayama, Izuma, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

“…The Raf murine sarcoma viral oncogene homolog B (BRAFV600E) mutation (MT) in metastatic colorectal cancer (CRC) is a well‐known prognostic indicator and a…”
Get full text

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors by Fukuda, Koshiro, Osumi, Hiroki, Yoshino, Koichiro, Nakayama, Izuma, Fukuoka, Shota, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Shinozaki, Eiji

“…Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic…”
Get full text

Heme Iron Coordination Structure of Heme Transport Protein HutB from Vibrio Cholerae by Uchida, Takeshi, Funamizu, Takumi, Ogura, Mariko, Ishimori, Koichiro

“…HutB is a putative heme transport protein located in the periplasmic space in Vibrio cholerae. Here, we purified HutB and characterized its heme binding…”
Get full text

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Mashima, Tetsuo, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Ota, Yumiko, Nakayama, Izuma, Takahari, Daisuke, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

“…Efficacy and safety of biweekly cetuximab plus irinotecan were evaluated to provide guidance for its use in Japan as third‐line treatment for pretreated…”
Get full text

Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer by Osumi, Hiroki, Ouchi, Kota, Shinozaki, Eiji, Takahashi, Shin, Ooki, Akira, Nakayama, Izuma, Wakatsuki, Takeru, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Ishioka, Chikashi

“…Purpose The CpG island methylator phenotype (CIMP), important for carcinogenesis, is a predictor of prognosis and chemotherapy sensitivity in colorectal cancer…”
Get full text

Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer by Kamiimabeppu, Daisaku, Wakatsuki, Takeru, Takahari, Daisuke, Fukuda, Naoki, Shimozaki, Keitaro, Osumi, Hiroki, Nakayama, Izuma, Ogura, Mariko, Ooki, Akira, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei

“…Background Alpha-Fetoprotein Producing Gastric Cancer (AFPGC) is an aggressive subgroup of gastric cancer. Recently ramucirumab has shown survival benefits in…”
Get full text

Long‐term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a‐muscularis mucosae and T1b‐submucosa by endoscopic resection followed by appropriate additional treatment by Naito, Sakiko, Yoshio, Toshiyuki, Ishiyama, Akiyoshi, Tsuchida, Tomohiro, Tokura, Junki, Namikawa, Ken, Tokai, Yoshitaka, Yoshimizu, Shoichi, Horiuchi, Yusuke, Hirasawa, Toshiaki, Asari, Takao, Mine, Shinji, Watanabe, Masayuki, Ogura, Mariko, Chin, Keisho, Fukuzawa, Masakatsu, Itoi, Takao, Fujisaki, Junko

“…Objectives Endoscopic resection (ER) is indicated for a wide range of superficial esophageal squamous cell carcinomas (ESCCs). We examined the long‐term…”
Get full text

Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers by Kobayashi, Kazuo, Sugiyama, Erika, Shinozaki, Eiji, Wakatsuki, Takeru, Tajima, Masataka, Kidokoro, Hiyori, Aoyama, Takeshi, Nakano, Yasuhiro, Kawakami, Kazuyoshi, Hashimoto, Koki, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Chin, Keisho, Nakayama, Izuma, Ooki, Akira, Takahari, Daisuke, Suzuki, Wataru, Yokokawa, Takashi, Minowa, Yuichi, Hiraoka, Tomoko, Suzuki, Kenichi, Sato, Hitoshi, Hama, Toshihiro, Yamaguchi, Kensei

“…Purpose The association between the pharmacokinetics and pharmacodynamics of regorafenib, a multiple tyrosine kinase inhibitor, remains unclear. This study…”
Get full text

Molecular Mechanism for Heme-Mediated Inhibition of 5-Aminolevulinic Acid Synthase 1 by Kitatsuji, Chihiro, Ogura, Mariko, Uchida, Takeshi, Ishimori, Koichiro, Aono, Shigetoshi

“…Mammalian 5-aminolevulinic acid synthase 1 (ALAS1), an isozyme expressed in all cell types, catalyzes the first reaction in the heme biosynthetic pathway in…”
Get full text

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study by Kitagawa, Yusuke, Osumi, Hiroki, Shinozaki, Eiji, Ota, Yumiko, Nakayama, Izuma, Suzuki, Takeshi, Wakatsuki, Takeru, Ogura, Mariko, Ooki, Akira, Takahari, Daisuke, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing…”
Get full text

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study by Suenaga, Mitsukuni, Wakatsuki, Takeru, Mashima, Tetsuo, Ogura, Mariko, Ichimura, Takashi, Shinozaki, Eiji, Nakayama, Izuma, Osumi, Hiroki, Ota, Yumiko, Takahari, Daisuke, Chin, Keisho, Seimiya, Hiroyuki, Yamaguchi, Kensei

“…Summary Background The effectiveness of reintroducing oxaliplatin for metastatic colorectal cancer (mCRC) refractory to both oxaliplatin and irinotecan was…”
Get full text